Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
NCT02658916 · Biogen · PHASE1 · terminated · last registry update 2020-05-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-03Results posted on the registry: AbbVie, Placebo + ABBV-8E12 (NCT02985879)
- 2021-02-03Also stopped (terminated): AbbVie, Placebo + ABBV-8E12 (NCT02985879)
- 2021-02-03Results posted on the registry: AbbVie, ABBV-8E12 + Placebo solution for IV infusion on Day 15 (NCT03391765)
- 2021-02-03Also stopped (terminated): AbbVie, ABBV-8E12 + Placebo solution for IV infusion on Day 15 (NCT03391765)
- 2020-12-21Results posted on the registry: Biogen, BIIB092 + Placebo (NCT03068468)
- 2020-12-21Also stopped (terminated): Biogen, BIIB092 + Placebo (NCT03068468)
- 2019-12-19Also stopped (terminated): University of California, San Francisco, BIIB092 (NCT03658135)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision